ATLPC0022650

ATLPC0022650 — ADMETatlas

Structure and chemistry interpretation

Chemical representationSMILES available

2D structure·RDKit.js

rendering molecule…

Canonical SMILES

CSCC[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C

Representation class

How the current release can interpret this identity chemically.

map backed

Parent-residue sequence

Residue string used for positional interpretation when available.

GFGMALKLLKKVL

HELM

Polymer notation for modified peptide representation when available.

GFGMALKLLKKVL{ct:Amid}

SMILES

Chemical graph string used for atom-level 2D depiction when available.

CSCC[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C

3D structure references3 references

Structure reference·

3D coordinates·PEPstrMOD predictionpredicted

PEPstrMOD prediction·reference selected·length 13 aa·confidence predicted

Link	Method	Confidence	Match
Open

Covalent topology & modificationsnone

No explicit topology annotation

No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.

Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.

5. Toxicity / Safety

What safety, toxicity, or tolerability evidence is attached?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Cytotoxicity metric % cytotoxicity Hemolysis metric % hemolysis

Hemolysis, cytotoxicity, clinical adverse-event context, and nonclinical safety context.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

% hemolysis14 measurements · 14 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
2	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
3	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
4	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
5	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
6	5 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
7	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
8	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
9	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
10	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open

1–10 / 14

Interpretation: Clinical and nonclinical context can guide interpretation, but it is not incidence, causality, or a comparable endpoint measurement.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

0 measurements

Distribution / Barrier

0 measurements

Metabolic & Proteolytic Stability

0 measurements

Excretion / Persistence

0 measurements

Toxicity / Safety

33 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Hemolysis Percent Observation

Cytotoxicity Metric

Hemolysis Metric

Cytotoxicity Percent Observation

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Toxicity / Safety Safety	Cytotoxicity Metric	75 μM	Comparable	Rat epithelial cells IEC-6, CRL-1592 · rat	Not specified	Open
2	Toxicity / Safety Safety	Cytotoxicity Percent Observation	18 %	Comparable	Human keratinocytes HaCat · human	Not specified	Open
3	Toxicity / Safety Safety	Hemolysis Metric	177 μM	Comparable	general	Not specified	Open
4	Toxicity / Safety Safety	Cytotoxicity Metric	87 μM	Comparable	Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
5	Toxicity / Safety Safety	Cytotoxicity Metric	21 μM	Comparable	Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
6	Toxicity / Safety Safety	Hemolysis Percent Observation	50 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
7	Toxicity / Safety Safety	Hemolysis Percent Observation	50 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
8	Toxicity / Safety Safety	Hemolysis Percent Observation	50 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
9	Toxicity / Safety Safety	Cytotoxicity Metric	56 μM	Comparable	Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
10	Toxicity / Safety Safety	Hemolysis Percent Observation	50 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open

1–10 / 33

Identity & reference map

Summary9 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 9
Measurements: 33
ATL peptide ID: ATLPC0022650

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

33 / 33

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 33

Different notation

Reported notation does not resolve to the current display sequence.

0 / 33

Reference map9 of 9 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
PubMed 22100226 Open	Safety Cytotoxicity Metric, Hemolysis Metric	No reported alias GFGMALKLLKKVLexact	17 identity 17 evidence
PubMed 24616110 Open	Safety Hemolysis Metric, Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	8 identity 8 evidence
PubMed 29185466 Open	Safety Cytotoxicity Percent Observation, Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	2 identity 2 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence
Reference link Open	Safety Hemolysis Percent Observation	No reported alias GFGMALKLLKKVLexact	1 identity 1 evidence

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0022650
Identity type: canonical sequence
ADMET endpoints: 4
Measurements: 33
Reference groups: 9
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0022650

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0022650' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

GFGMALKLLKKVL{ct:Amid}

Hemolysis metric6 measurements · 6 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	177 μM	Comparable	general	Not specified	Open
2	160 μM	Comparable	general	Not specified	Open
3	> 200 μM	Comparable	general	Not specified	Open
4	152 μM	Comparable	general	Not specified	Open
5	> 200 μM	Comparable	general	Not specified	Open
6	> 200 μM	Comparable	general	Not specified	Open

% cytotoxicity1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	18 %	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open

Cytotoxicity metric12 measurements · 12 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	87 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
2	21 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
3	56 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
4	52 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
5	21 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
6	28 μM	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
7	75 μM	Comparable	Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat	Not specified	Open
8	27 μM	Comparable	Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat	Not specified	Open
9	28 μM	Comparable	Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat	Not specified	Open
10	> 100 μM	Comparable	Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat	Not specified	Open

1–10 / 12

ATLPC0022650

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Toxicity / Safety

Evidence summary

6. Evidence landscape

Evidence landscape and measurement index

7. Identity & reference map

Identity & reference map

8. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record